Safety of GVHD prophylaxis in Haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide in combination with thymoglobulin

Safety of GVHD prophylaxis in Haploidentical hematopoietic stem cell transplantation with posttransplant cyclophosphamide in combination with thymoglobulin - Safety of GVHD prophylaxis in Haploidentical hematopoietic stem cell transplantation

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000014472

Enrollment

Registered

2014-07-04

Start date

2014-07-04

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematopoietic malignancy

Interventions

Conditioning regimen and GVHD prophylaxis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patient with chemorefractory hematological malignancy, no HLA matched donner but HLA haploidentical donner

Exclusion criteria

Exclusion criteria: Cases with a sufficient amount (2.0x106/kg CD34-positive cells) could not be harvested peripheral blood hematopoietic stem cells from donor

Design outcomes

Primary

Measure	Time frame
Engraftment and survival without grade III-IV acute GVHD at day60	—

Secondary

Measure	Time frame
1.1 year progression-free survival and overall survival 2.1 year non relapse mortarity 3.primary graft failure 4.secondary graft failure 5.acute and chronic GVHD	—

Countries

Japan

Contacts

Public ContactKazuhiro Kohno

Oita University Faculity of Medicine Department of Oncology and Hematology

kkohno@oita-u.ac.jp097-549-4411

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026